42C — IX Biopharma Income Statement
0.000.00%
Last trade - 00:00- SG$520.60m
- SG$511.67m
- SG$6.85m
Annual income statement for IX Biopharma, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14.4 | 5.91 | 5.96 | 7.77 | 6.85 |
| Cost of Revenue | |||||
| Gross Profit | 12.3 | 2.32 | 1.05 | 2.04 | 2.43 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18.5 | 15.6 | 15.9 | 17.9 | 14.8 |
| Operating Profit | -4.1 | -9.71 | -9.98 | -10.1 | -7.98 |
| Net Income Before Taxes | -4.1 | -9.71 | -9.98 | -10.1 | -7.98 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.6 | -9.62 | -10.8 | -10.1 | -7.99 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.6 | -9.62 | -10.8 | -10.1 | -7.99 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.6 | -9.62 | -10.8 | -10.1 | -7.99 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.006 | -0.012 | -0.014 | -0.012 | -0.008 |